Why the study?
Does the human iPSC-cardiomyocyte arrhythmic risk (hCAR) model accurately predict clinical arrhythmia and QT prolongation for diverse compounds?
Population
Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs)
Comparison
88 marketed and 30 internal discovery compounds vs Time-matched vehicle control group
Design
Preclinical
Authors
Loading...
Threshold ≤10 μM in hCAR assay aids in vitro TdP classification; leaves open clinical translation pending human validation studies.
Does the human iPSC-cardiomyocyte arrhythmic risk (hCAR) model accurately predict clinical arrhythmia and QT prolongation for diverse compounds?
The human cardiomyocyte arrhythmic risk (hCAR) assay using hiPS-CMs demonstrates increased performance over existing preclinical tools, such as hERG inhibition, in predicting clinical QT prolongation, arrhythmia, and Torsade de Pointes.
Guo et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: